Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.
OBJECTIVE
This study sought to examine the effect of ziprasidone on olanzapine or clozapine-associated medical morbidity such as insulin resistance, diabetes mellitus (DM) and impaired fasting glucose, obesity, and hyperlipidemia in patients with schizophrenia or schizoaffective disorder.


METHODS
This was a 6-week, open label trial of ziprasidone 160 mg/day added to a stable dose of olanzapine or clozapine in 21 schizophrenia or schizoaffective patients with DM, impaired fasting glucose, or insulin resistance.


RESULTS
Ten olanzapine-treated subjects and 11 clozapine-treated subjects were enrolled in the study. There were no significant differences between the two groups at baseline for age, gender, education, ethnicity, BMI, cholesterol levels, or fasting glucose. At week 6, there were no significant changes in weight, BMI, cholesterol levels, or fasting glucose. There was no significant difference in psychotic, negative, or depressive symptoms. QTc significantly increased at week 2 but not at week 6.


CONCLUSIONS
The addition of 160 mg/day of ziprasidone was well tolerated but did not produce significant improvement in fasting glucose, insulin resistance, hyperlipidemia or lead to weight loss in olanzapine- or clozapine-treated subjects with schizophrenia or schizoaffective disorder.
Henderson
David C
DC
Schizophrenia Program, Massachusetts General Hospital, Boston, Massachusetts, USA. dchenderson@partners.org
Fan
Xiaoduo
X
Copeland
Paul M
PM
Sharma
Bikash
B
Borba
Christina P
CP
Forstbauer
Sharon I
SI
Miley
Kate
K
Boxill
Ryan
R
Freudenreich
Oliver
O
Cather
Corrine
C
Evins
Anne E
AE
Goff
Donald C
DC
D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000494:pharmacology / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D002908:Chronic Disease; D003024:Clozapine / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D009017:Morbidity; D000077152:Olanzapine; D010879:Piperazines / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D013844:Thiazoles / Q000627:therapeutic use*; D013997:Time Factors
D014150:Antipsychotic Agents; D001786:Blood Glucose; D010879:Piperazines; D013844:Thiazoles; D001569:Benzodiazepines; C092292:ziprasidone; D003024:Clozapine; D000077152:Olanzapine